secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0000950170-24-002745
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan Oncology reports $468.3M cash as of Dec 31, 2023; runway into H2 2026
------------------------------------------------------------------------------

- Unaudited cash, equivalents, investments, and interest receivable totaled $468.3M as of Dec 31, 2023.
- Company expects cash runway into second half of 2026 under current operating plan.
- Preliminary figure subject to change upon completion of financial closing procedures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000095017024002745/0000950170-24-002745-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000095017024002745/cgem-20240108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-002745

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer